ECM
ENSC icon

Evergreen Capital Management’s Ensysce Biosciences ENSC Stock Holding History

Evergreen Capital Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$13K – 606
2022
Q1 		$13K Sell
3
-1
-25% -$6.61K ﹤0.01% 656
2021
Q4 		$66K Hold
4
– – ﹤0.01% 626
2021
Q3 		$43K Buy
+4
New +$78.2K ﹤0.01% 579

Other funds holding ENSC

HVCM
HG Vora Capital Management New York $197M AUM 17.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Evergreen Capital Management's ENSC Position: Q2 2022 in Review

Evergreen Capital Management sold out of Ensysce Biosciences (ENSC) in Q2 2022, closing a stake of 3 shares — an estimated $13K sold.

Evergreen Capital Management first reported a position in ENSC in Q3 2021 and held it in 3 quarters. The position peaked at $66K in Q4 2021. 16 funds tracked by Wall St. Rank hold ENSC as of Q2 2022.

  • Evergreen Capital Management reported no remaining Ensysce Biosciences position as of Q2 2022 after selling out during the quarter.
  • Evergreen Capital Management sold 3 Ensysce Biosciences shares in Q2 2022, an estimated $13K.
  • Evergreen Capital Management first reported a position in Ensysce Biosciences in Q3 2021 and held it in 3 quarters.
  • Evergreen Capital Management's Ensysce Biosciences position peaked at $66K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2022.

Based on Evergreen Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.